France Leads EU in Reimbursing MiYOSMART Lenses for Childhood Myopia

France will begin reimbursing Hoya Vision Care’s MiYOSMART myopia-control spectacle lenses for eligible children starting July 1, becoming the first country in the European Union to offer public coverage for this innovative technology. The decision follows approval by the French Health Authority (HAS).

Targeting High and Rapidly Progressing Myopia

Eligible for reimbursement are children aged 6 to 15 with high myopia (–6.00 D or more) or rapidly progressing myopia (worsening by –0.50 D or more per year). This condition affects over 500,000 children in France, and public coverage aims to broaden access to effective management.

Technology Behind MiYOSMART Lenses

MiYOSMART lenses utilize Hoya’s patented Defocus Incorporated Multiple Segments (D.I.M.S.) technology, providing a noninvasive, safe, and effective way to slow myopia progression in children. Supported by more than eight years of clinical data, studies show an average 60% reduction in progression in myopia compared to standard single-vision lenses.

Industry and Clinical Support

“This milestone is a hugely significant step forward for myopia management,” stated Jean-Michel Lambert, General Manager of Hoya Vision Care France.  “At Hoya Vision Care, we believe that ‘Every Child Deserves Better.’ Thanks to the dedication of professionals and organizations who share this vision, we are proud to play our part in creating a healthier future where every child has the opportunity to see clearly and reach their full potential.”

Hoya secured MiYOSMART’s addition to France’s List of Products and Services (LPP), enabling reimbursement via national health insurance. Additional coverage may be available through private supplemental insurance, aiming to reach as many eligible children as possible.

Call for Global Action

“As a society, we need to take urgent action to mitigate the burden of myopia,” said Prof. Dominique Bremond-Gignac, a prominent pediatric ophthalmologist. “The reimbursement of MiYOSMART in France is a significant step forward in our fight against childhood myopia. I hope this will spark a global movement—ensuring effective treatments are accessible and no child’s vision is irreversibly compromised.”

References:
1. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. British Journal of Ophthalmology.

2. Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. British Journal of Ophthalmology 2022;106:1110-1114.

3. Lam CSY, Tang WC, Zhang HY, Lee PH, Tse DYY, Qi H, Vlasak N, To CH. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023 Apr 4;13(1):5475.

4. Leung TW, et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Poster number A0113. Presented 6th May, ARVO 2025

5. Haute Autorité de Santé (HAS) Public Report. French Health Authority; 2022 Mar.

6. Tricard D, Marillet S, Ingrand P, Bullimore MA, Bourne RRA, Leveziel N. Progression of myopia in children and teenagers: anationwide longitudinal study. Br J Ophthalmol. 2022;106(8):1104-9

7. World Health Organization. SPECS 2030: Vision and mission.

8. Based on the number of MiYOSMART spectacle lenses sold according to HOYA’s sales data on file as of April 25.